CervoMed Inc.

For the period ended Dec 31, 2025. Filed Mar 13, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 13, 2026

CRVO$1.43+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 13, 2026	CERVOMED INC.
	By:	/s/ John Alam, MD John Alam, MD President, Chief Executive Officer and Director (Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Joshua S. Boger, PhD
Name and Signature	Title	Date
/s/ John Alam, MD	President, Chief Executive Officer and Director	March 13, 2026
John Alam, MD	(Principal Executive Officer)
/s/ William Elder	Chief Financial Officer and General Counsel	March 13, 2026
William Elder	(Principal Financial Officer)
/s/ Joshua S. Boger, PhD	Chair of the Board	March 13, 2026
/s/ Sylvie Grégoire, PharmD	Director	March 13, 2026
Sylvie Grégoire, PharmD
/s/ Jane H. Hollingsworth, JD	Director	March 13, 2026
Jane H. Hollingsworth, JD
/s/ Jeffrey V. Poulton	Director	March 13, 2026
Jeffrey V. Poulton
/s/ David Quigley	Director	March 13, 2026
David Quigley
/s/ Marwan Sabbagh, MD	Director	March 13, 2026
Marwan Sabbagh, MD
/s/ Frank Zavrl	Director	March 13, 2026
Frank Zavrl

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.